Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
Clinical Breast Cancer · 2026-11 · 26 (11) · 9-16
DOI: 10.1016/j.clbc.2026.09.003 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Clinical Breast Cancer, 2026-11. Verfasst von Alexander Douglas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Internal Medicine, Oklahoma State …. Hauptthemen laut MEDLINE: Breast Neoplasms, Randomized Controlled Trials as Topic, Patient Reported Outcome Measures. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Randomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standardization of PROs in research led to the development of the International Consortium for Health Outcomes Measurement (ICHOM). ICHOM has published literature describing its methodology and the development of a breast cancer core outcome set (COS). Our primary aim was to investigate the completeness of reporting within breast cancer clinical trial registries after the publication of the ICHOM breast cancer COS. PATIENTS AND METHODS: A cross-sectional analysis was performed using the ClinicalTrials.gov database. COS information and trial characteristics were extracted from the trial registries in a masked manner. The completeness of reporting of the COS was analyzed. RESULTS: After our final inclusion criteria were applied, our final sample of 237 RCTs was assessed. Systemic therapy was the most commonly reported type of intervention (216/237; 91.1%). The average completeness of reporting was only 28.5% across all of the intervention types, and over three-fourths of the RCTs reported less than half of the COS measures. CONCLUSION: As PROs and patient-centered healthcare are coming to the forefront of medicine, particularly in oncology, a standardized COS, like ICHOM's, offers trialists an endorsed resource to thoroughly capture and report the patient perspective in clinical research. We have offered recommendations to improve the reporting of PRO measures to capture within breast cancer RCTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Internal Medicine, Oklahoma State University Medical Center, Tulsa, OK.
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS. Electronic address: tmoore20@ku…
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Pathology, New York University Langone Health, New York, NY.
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Internal Medicine, Methodist Dallas Medical Center, Dallas, TX.
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Radiology, Oklahoma State University Medical Center, Tulsa, OK.
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK; Department of Obstetrics and Gynecology, Oklahoma State University Medical Center, Tulsa, OK.
Zitieren
APA
Douglas, A., Moore, T., Hughes, G., Bacani, R., Szymanski, B., Moody, M., Syed, F., & Vassar, M. (2026). Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study. Clinical Breast Cancer, 26(11), 9-16. https://doi.org/10.1016/j.clbc.2026.09.003
Vancouver
Douglas A, Moore T, Hughes G, Bacani R, Szymanski B, Moody M, et al. Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study. Clinical Breast Cancer. 2026;26(11):9-16. doi:10.1016/j.clbc.2026.09.003
BibTeX
@article{Douglas2026,
author = {Douglas, Alexander and Moore, Ty and Hughes, Griffin and Bacani, Rigel and Szymanski, Brett and Moody, Mackenzie and Syed, Farzeen and Vassar, Matt},
title = {Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {11},
pages = {9--16},
doi = {10.1016/j.clbc.2026.09.003}
}
EUVIMED